Clinical Trials
94 trialsNCT07599995 2026-05-20
GENE
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT06282575 2026-05-11
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07466238 2026-05-08
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Phase NA Recruiting
NCT07569679 2026-05-06
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Phase 2 Recruiting
NCT07030140 2026-05-01
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT03406299 2026-04-09
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT07107750 2026-04-03
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT07398339 2026-02-09
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Phase 2 Recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06546969 2025-12-10
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Phase 1 Recruiting
NCT06001658 2025-12-03
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05482893 2025-11-04
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT03044587 2025-10-01
NIFE
AIO-Studien-gGmbH
Phase 2 Completed
NCT06893380 2025-09-15
GENTIS
CHA University
Recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT07109167 2025-08-07
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07062263 2025-07-14
TAB-2
Tata Memorial Centre
Phase 3 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT03478488 2025-05-29
KN035-BTC
3D Medicines
Phase 3 Active not recruiting
NCT06975917 2025-05-16
TOG-SAFRADJU
Ankara University
Active not recruiting
NCT06214572 2025-04-11
RUGB
Tata Memorial Centre
Phase 2/3 Recruiting
NCT06903273 2025-03-30
TisGCS for BTC
National Cheng-Kung University Hospital
Phase 2 Not yet recruiting
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT06818773 2025-02-10
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Eastern Hepatobiliary Surgery Hospital
Phase 4 Not yet recruiting
NCT06465563 2025-01-27
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT03673072 2024-11-12
GAIN
Krankenhaus Nordwest
Phase 3 Completed
NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT06611345 2024-10-26
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase NA Recruiting
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06569225 2024-08-26
NEOLANGIO
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03046862 2024-04-19
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Unknown
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT03260712 2023-11-03
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated